FDAnews
www.fdanews.com/articles/132124-fda-approves-amgen-8217-s-xgeva-to-prevent-bone-disease-due-to-tumors

FDA Approves Amgen’s Xgeva to Prevent Bone Disease Due to Tumors

November 22, 2010
The FDA has approved Amgen’s Xgeva to prevent skeletal-related events in patients with bone metastases from solid tumors, giving the drug a broader than expected label. The drug’s indication for solid tumors does not specify breast or prostate tumors, the two broadly studied solid tumors, Baird analyst Christopher Raymond said. Therefore, the drug could be used for lung, renal and other solid tumors. Xgeva (denosumab), which will cost $1,650 per month, is expected to bring in about $172 million next year and $565 million in fiscal 2013, Raymond added.
Drug Industry Daily